Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

RLYP Insider Trading

RLYP | Market Equity

Comprehensive Trading Performance Summary

The investment history of corporate insiders at RLYP provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2016-08-19 01:47 2016-08-16 Montgomery Monte Officer - Chief Accounting Officer SELL $31.92 510 $16,279 12,539 -3.9%
2016-08-19 00:23 2016-08-17 DONDERO JAMES D 10% owner BUY $31.92 500 $15,961 128,500 +0.4%
2016-08-16 01:21 2016-08-11 DONDERO JAMES D 10% owner SELL $31.96 37,000 $1,182,520 128,000 -22.4%
2016-07-27 01:04 2016-07-22 ORBIMED ADVISORS LLC 10% owner SELL $32.00 4,043,600 $129,388,326 3,356,400 -54.6%
2016-06-09 00:23 2016-06-07 Torley Helen Director SELL $19.32 1,013 $19,570 1,237 -45.0%
2016-06-09 00:21 2016-06-07 Hillan Kenneth J. Director SELL $19.31 1,013 $19,563 1,237 -45.0%
2016-06-09 00:19 2016-06-07 Butler John P. Director SELL $19.32 1,013 $19,570 2,849 -26.2%
2016-06-09 00:18 2016-06-07 HASTINGS PAUL J Director SELL $19.32 1,013 $19,573 2,495 -28.9%
2016-06-09 00:22 2016-06-07 SPIEGELMAN DANIEL K Director SELL $19.31 1,013 $19,562 1,237 -45.0%
2016-06-09 00:17 2016-06-07 MCGIRR DAVID W J Director SELL $19.34 1,013 $19,588 2,729 -27.1%
2016-03-17 02:26 2016-03-15 Schuetz Thomas J. Director BUY $13.39 30,000 $401,832 33,962 +757.2%
2016-03-17 02:27 2016-03-16 BALL KRISTINE M Officer - Chief Financial Officer & SVP BUY $12.15 7,000 $85,050 28,290 +32.9%
2016-01-05 01:27 2015-12-31 Stahl Wilhelm Officer - SVP, Chief Technology Officer OPT+S $28.53 20,000 $570,558 14,853 0.0%
2015-12-24 01:06 2015-12-21 ORBIMED ADVISORS LLC 10% owner SELL $27.18 500,000 $13,588,000 7,400,000 -6.3%
2015-12-10 04:24 2015-12-07 Orwin John A Director, Officer - President & CEO OPT+S $28.28 15,000 $424,133 54,375 0.0%
2015-12-10 04:23 2015-12-07 Berman Lance Officer - Chief Medical Officer and SVP OPT+S $29.77 30,750 $915,526 21,290 0.0%
2015-12-05 01:50 2015-12-02 Orwin John A Director, Officer - President & CEO OPT+S $25.00 40,000 $1,000,000 59,375 0.0%
2015-10-23 01:00 2015-10-22 ORBIMED ADVISORS LLC 10% owner BUY $12.56 500,000 $6,280,150 7,900,000 +6.8%
2015-09-04 01:21 2015-09-02 BALL KRISTINE M Officer - Chief Financial Officer & SVP SELL $22.96 646 $14,832 15,040 -4.1%
2015-08-20 02:42 2015-08-17 Krasnow Ronald A. Officer - See Remarks SELL $24.75 522 $12,922 10,478 -4.7%
2015-08-20 02:41 2015-08-17 Corbett Mary Officer - Senior VP, Human Resources SELL $24.72 522 $12,906 10,478 -4.7%
2015-08-20 02:41 2015-08-17 Berman Lance Officer - Chief Medical Officer and SVP SELL $24.77 710 $17,586 15,040 -4.5%
2015-08-20 02:40 2015-08-17 Orwin John A Director, Officer - President & CEO SELL $24.84 5,000 $124,184 42,500 -10.5%
2015-08-20 02:39 2015-08-17 Stahl Wilhelm Officer - SVP, Chief Technology Officer SELL $24.70 522 $12,894 10,478 -4.7%
2015-08-20 02:39 2015-08-17 Lockey Claire Officer - See Remarks SELL $24.69 522 $12,888 10,478 -4.7%
2015-08-20 02:40 2015-08-17 BALL KRISTINE M Officer - Chief Financial Officer & SVP SELL $24.78 710 $17,597 15,040 -4.5%
2015-08-04 03:43 2015-07-30 Orwin John A Director, Officer - President & CEO OPT+S $33.56 30,000 $1,006,797 25,000 0.0%
2015-06-16 01:40 2015-06-11 Butler John P. Director SELL $34.62 1,100 $38,087 3,862 -22.2%
2015-06-16 01:39 2015-06-11 Schuetz Thomas J. Director SELL $34.57 1,000 $34,571 3,962 -20.2%
2015-06-16 01:41 2015-06-11 HASTINGS PAUL J Director SELL $34.63 1,454 $50,359 3,508 -29.3%
2015-06-16 01:42 2015-06-11 MCGIRR DAVID W J Director SELL $34.67 1,220 $42,300 3,742 -24.6%
2015-06-03 03:24 2015-05-29 Orwin John A Director, Officer - President & CEO OPT+S $36.42 33,555 $1,222,150 30,000 0.0%
2015-05-21 03:30 2015-05-18 ORBIMED ADVISORS LLC 10% owner SELL $34.13 1,457,551 $49,746,216 7,400,000 -16.5%
2015-05-14 02:00 2015-05-11 VEITINGER KLAUS R DR Director OPT+S $36.06 5,834 $210,387 2,712 0.0%
2015-04-14 01:09 2015-04-10 VEITINGER KLAUS R DR Director OPT+S $35.35 5,832 $206,179 2,712 0.0%
2015-03-13 01:21 2015-03-10 VEITINGER KLAUS R DR Director OPT+S $38.67 5,834 $225,594 2,712 0.0%
2015-03-07 03:19 2015-03-04 Lockey Claire Officer - See Remarks OPT+S $40.00 10,000 $400,000 5,500 0.0%
2015-03-06 04:24 2015-03-03 BALL KRISTINE M Officer - Chief Financial Officer & SVP OPT+S $40.68 3,519 $143,137 7,500 0.0%
2015-02-28 04:55 2015-02-25 Krasnow Ronald A. Officer - See Remarks SELL $39.00 10,348 $403,572 5,500 -65.3%
2015-02-26 02:33 2015-02-24 Berman Lance Officer - Chief Medical Officer and SVP OPT+S $38.19 5,000 $190,949 7,500 0.0%
2015-02-25 19:44 2015-02-23 Krasnow Ronald A. Officer - See Remarks SELL $39.00 10,000 $390,000 15,848 -38.7%
2015-02-11 05:06 2015-02-10 VEITINGER KLAUS R DR Director OPT+S $32.12 5,834 $187,359 2,712 0.0%
2015-01-24 05:45 2015-01-21 Krasnow Ronald A. Officer - See Remarks OPT+S $35.00 55,000 $1,925,000 25,848 0.0%
2015-01-24 05:43 2015-01-21 Lockey Claire Officer - See Remarks OPT+S $35.00 5,000 $175,000 5,500 0.0%
2015-01-24 05:44 2015-01-21 BALL KRISTINE M Officer - Chief Financial Officer & SVP OPT+S $36.00 3,000 $108,000 7,500 0.0%
2015-01-17 03:43 2015-01-14 Krasnow Ronald A. Officer - See Remarks OPT+S $33.58 5,000 $167,895 25,848 0.0%
2015-01-14 19:15 2015-01-12 VEITINGER KLAUS R DR Director OPT+S $32.33 5,834 $188,589 2,712 0.0%
2014-12-13 03:11 2014-12-10 VEITINGER KLAUS R DR Director OPT+S $32.16 14,169 $455,682 2,712 0.0%
2014-12-12 00:55 2014-12-09 5AM Partners III, LLC 10% owner SELL $30.04 589,637 $17,712,695 47,502 -92.5%
2014-12-11 04:29 2014-12-09 Lockey Claire Officer - See Remarks OPT+S $30.00 8,000 $240,000 5,500 0.0%
SHOW ENTRIES

How to Interpret $RLYP Trades

Not every insider transaction in RLYP is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $RLYP shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for RLYP

Insider activity data for RLYP is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $RLYP, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.